Compare organizations

ECHAMP, the European Coalition on Homeopathic & Anthroposophic Medicinal Products, represents the majority of the companies active in the production and distribution of those products in the EU. We endorse the rights of more than 110 million patients and consumers in the EU to have easy and comprehensive access to reliable homeopathic and anthroposophic medicinal products which meet the highest standards of quality…

A FIT PHARMACEUTICAL LEGISLATION TO BENEFIT E.U. CITIZENS AND HEALTH SYSTEMS AESGP supports a pragmatic and risk-based regulatory framework that fosters a stronger role for self-care and prevention. The current structure is overall fit for purpose although some issues may arise from divergent interpretation, disharmonised application and addition of gold plating or administrative elements.

AESGP expresses support for the Commission Proposal to revise the EU general pharmaceutical legislation. We believe this long-awaited revision will consolidate and streamline legislation which underwent multiple updates over the past 20 years. While AESGP members acknowledge the legislation's goals, we raise concerns on unintended consequences for non-prescription medicines (NPMs).

ECHAMP, the European Coalition on Homeopathic and Anthroposophic Medicinal Products, represents an EU-based industry that has been serving the European market for decades. EU legislation for homeopathic medicinal products has deep roots in their broad use in the Member States; the EU being the global centre of expertise in manufacturing, quality standards and regulation of this industry.

ECHAMP, the European Coalition on Homeopathic and Anthroposophic Medicinal Products, represents an EU-based industry that has been serving the European market for decades. EU legislation for homeopathic medicinal products has deep roots in their broad use in the Member States; the EU being the global centre of expertise in manufacturing, quality standards and regulation of this industry.

ECHAMP welcomes and supports this important initiative, which will be an essential cornerstone for the Pharmaceutical Strategy. We are pleased to see that the proposal emphasizes the importance of allowing patients and citizens control over their own health data and of exploring how to facilitate the inclusion of citizen-generated data.

LET THE KNOWLEDGE CONTAINED IN DATA OPEN DOORS TO THE FUTURE OF HEALTHCARE AESGP welcomes the European Commission’s Combined Evaluation Roadmap and Inception Impact Assessment on A European Health Data Space and its ambition to introduce innovation, to take advantage of digital technology developments and to deliver concrete results to improve healthcare in Europe.

Accompany enhanced data sharing with necessary (digital) literacy programs AESGP welcomes the European Commission’s proposal for a regulation on the European Health Data Space and its ambition to support innovation, take advantage of digital technology developments and deliver concrete results to improve healthcare in Europe.

ECHAMP welcomes this consultation and we are pleased that possible misalignment of some fees with the underlying costs will be addressed. We fully support the objective of ensuring a fair distribution of fees. We ask for your specific attention for the category of homeopathic medicinal products.

Please see below the AESGP comments on the European Commission proposal on updating the rules on fees payable to the European Medicines Agency. The detailed comments are provided in the attached document. The EMA is currently funded at 86% by fees, 13% by EU contribution and 1% by other sources.